Post‐transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high‐risk acute myeloid leukaemia
- 17 December 2014
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 169 (5) , 756-759
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Toxic encephalopathy after exposure to azacitidineLeukemia & Lymphoma, 2014
- A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemiaBlood, 2013
- Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantationBlood, 2012
- Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndromeCancer, 2010
- In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemiaBlood, 2010
- Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation settingBlood, 2010
- Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2007
- Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase SykLeukemia, 2006
- Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicinBlood, 2001
- 5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemiasBlood, 1984